Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence

2021 ◽  
Vol 105 ◽  
pp. 110126 ◽  
Author(s):  
Orly Lipsitz ◽  
Roger S. McIntyre ◽  
Nelson B. Rodrigues ◽  
Tyler S. Kaster ◽  
Danielle S. Cha ◽  
...  
Keyword(s):  
Repeated Dose ◽  
Treatment Center ◽  
Center Of Excellence ◽  
Intravenous Ketamine ◽  
Rapid Treatment

Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence

2020 ◽  
Vol 19 (8) ◽  
pp. 1031-1040 ◽  
Author(s):  
Nelson B. Rodrigues ◽  
Roger S. McIntyre ◽  
Orly Lipsitz ◽  
Yena Lee ◽  
Danielle S. Cha ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Treatment Center ◽  
Major Depressive ◽  
Center Of Excellence ◽  
Rapid Treatment

Intravenous ketamine for rapid treatment of major depressive disorder in the general medical hospital

2021 ◽  
Vol 14 (10) ◽  
pp. e239587
Author(s):  
Siobhan Helen Gee ◽  
Camille Wratten ◽  
Ruth Cairns ◽  
Alastair Santhouse ◽  
David Taylor
Keyword(s):  
Mental Health ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Oral Treatment ◽  
Medical Problem ◽  
Major Depressive ◽  
Medical Settings ◽  
Mental Health Settings ◽  
Intravenous Ketamine ◽  
Rapid Treatment

Major depressive disorder (MDD) is common in general medical settings, and can usually be treated with conventional oral antidepressants. For some patients, however, oral treatment is refused or not possible, and the untreated symptoms can have a significant impact on the treatment of the acute medical problem. Use of intravenous ketamine has been widely reported in mental health settings for the treatment of MDD. We describe use of intravenous ketamine in a general medical hospital for the treatment of MDD in an 83-year-old male patient who refused food, fluid and medical investigations following a stroke.

Sign in / Sign up

Export Citation Format

Share Document